MODERATE TO SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE TO SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Long-Term skin treatment study seeks to confirm safety for eczema patients
Disease control CompletedThis study followed 79 adults with moderate to severe atopic dermatitis (eczema) who had already participated in earlier research on the drug SHR-1819. The main goal was to gather more information on the long-term safety and effectiveness of the injection. Participants continued …
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New data on eczema drug for understudied skin tones
Disease control CompletedThis study aimed to gather more information on the safety and effectiveness of the drug dupilumab specifically for people with skin of color who have moderate-to-severe eczema (atopic dermatitis). It involved 124 adolescent and adult participants and measured how well the drug im…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
Eczema drug put to the test: does it block vaccine protection?
Disease control CompletedThis study checked if a new eczema medication called rocatinlimab affects how well vaccines work. Researchers compared 221 adults with moderate-to-severe eczema who received either the drug or a placebo. They measured participants' immune responses to tetanus and meningococcal va…
Matched conditions: MODERATE TO SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 04, 2026 15:30 UTC